MFN News Items | Nanologica

Nanologica’s Interim Report Jan-Mar 2022

29 April, 2022

PERIOD IN BRIEF FINANCIAL SUMMARY Net sales for the first quarter amounted to TSEK 270 (5,622) The operating result amounted to TSEK -15,592 (-6,768) Result after tax amounted to TSEK -15,915 (-7,845) Earnings per share before and after dilution were SEK -0.57 (-0.28) Cash and cash equivalents amounted to TSEK 3,969 (57,069) as per March 31, 2022 SIGNIFICANT EVENTS IN THE FIRST QUARTER In January, a credit facility of up to MSEK 50 was signed

Nanologicas delårsrapport jan-mar 2022

29 April, 2022

FINANSIELL SAMMANFATTNING · Nettoomsättningen för första kvartalet uppgick till 270 TSEK (5 622) · Rörelseresultatet uppgick till -15 592 TSEK (-6 768) · Resultatet efter skatt uppgick till -15 915 TSEK (-7 845) · Resultat per aktie före och efter utspädning var -0,57 SEK (-0,28) · Likvida medel uppgick per den 31 mars 2022 till 3 969 TSEK (57 069) VÄSENTLIGA HÄNDELSER UNDER FÖRSTA KVARTALET · I januari tecknas en lånefacilitet om upp till 50 MSEK

Nanologica takes out loan of MSEK 20 within agreed credit facility

25 April, 2022

Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB. The loan is taken out to cover the company's temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, MSEK 20 remains of the credit facility. For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

Nanologica upptar lån om 20 MSEK inom avtalad kreditfacilitet

25 April, 2022

Nanologica AB (publ) har upptagit ett lån om 20 MSEK ur den kreditfacilitet som i januari avtalades med Flerie Invest AB. Lånet upptas i syfte att överbrygga bolagets tillfälliga finansiella behov i väntan på förväntade kassaflöden från verksamheten inom preparativ kromatografi. Efter lånet återstår 20 MSEK av kreditfaciliteten. För ytterligare information, vänligen kontakta: Johanna Johansson, Director IR, Communications and Marketing Tel: +46 72 211 21 90 eller e-post: ir@nanologica.com Om Nanologica AB (publ) Nanologica tillverkar, utvecklar

Nanologica Expands Launch Road Show after Good Reception

12 April, 2022

After a successful first activity of the global launch of the company's silica for preparative chromatography, NLAB Saga®, Nanologica expands the road show with participation at additional chromatography conferences. The launch of Nanologica’s silica for preparative chromatography started at the Purify'22 Chromatography Purification Conclave on April 7 in Hyderabad, India, where the products received a very good reception. In light of this, Nanologica has expanded its road show with additional conferences for chromatography. The company

Nanologica utökar lanseringsturné efter mycket gott mottagande

12 April, 2022

Efter en lyckad första aktivitet på den globala lanseringsturnén av bolagets silika för preparativ kromatografi, NLAB Saga[®], utökar Nanologica turnén med deltagande vid ytterligare kromatografikonferenser. Lanseringen av bolagets silika för preparativ kromatografi startade på konferensen Purify'22 Chromatography Purification Conclave den 7 april i Hyderabad, Indien, där produkterna fick ett mycket gott mottagande. Nanologica har mot bakgrund av detta utökat sin lanseringsturné med ytterligare konferenser för kromatografi. Bolaget planerar att delta vid följande konferenser under 2022:

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.